Idiopathic inflammatory myopathies (IIM) and associated inflammation, limited mobility, glucocorticoid treatment, can have a negative impact on metabolic disease, atherogenesis, and cardiovascular risk. The aim was to assess the cardiovascular risk in IIM and healthy controls (HC) and the association with disease-specific features.